Patient-reported tolerability of adverse events in phase 1 trials

ESMO Open

Volumn 2, Issue 2, 2017, Pages

  Henon, Clémence ^a   Lissa, Delphine ^a   Paoletti, Xavier ^a,b   Thibault, Constance ^a   Tourneau, Christophe Le ^c,d   Lanoy, Emilie ^a,b   Hollebecque, Antoine ^a   Massard, Christophe ^a   Soria, Jean Charles ^a,d   Postel Vinay, Sophie ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c INSTITUT CURIE   (France)

^d INSERM   (France)

Author keywords

adverse event; Dose limiting toxicity; patient reported outcome; phase 1; tolerability

Indexed keywords

EID: 85051252335     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2016-000148     Document Type: Article

References (14)

1. Arbuck SG. Workshop on phase I study design. Ninth NCI/EORTC new drug development symposium, Amsterdam, March 12, 1996. Ann Oncol 1996;7:567-73.
2. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
3. Le Tourneau C, Razak AR, Gan HK, et al. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer 2011;47:1468-75.
4. Postel-Vinay S, Gomez-Roca C, Molife LR, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 2011;29:1728-35.
5. Soria JC. Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly? Eur J Cancer 2011;47:1443-5.
6. Postel-Vinay S, Collette L, Paoletti X, et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents-dose-limiting toxicity and toxicity assessment recommendation group for early trials of targeted therapies, an european organisation for research and treatment of cancer-led study. Eur J Cancer 2014;50:2040-9.
7. Paoletti X, Le Tourneau C, Verweij J, et al. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. Eur J Cancer 2014;50:2050-6.
8. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PROCTCAE). JAMA Oncol 2015;1:1051-9.
9. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11.
10. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 2016;34:2452-9.
11. Hershman DL. Sticking to it: improving outcomes by increasing adherence. J Clin Oncol 2016;34:2440-2.
12. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007;25:5121-7.
13. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JNCI 2014;106:dju244.
14. Anota A, Boulin M, Dabakuyo-Yonli S, et al. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open 2016;6:e010696.